Skip to main content

Table 2 Effect of empagliflozin on morphometric parameters of different organs and body weight in the lean control and ZSF1 groups

From: Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

 

Control

Empa

ZSF1

ZSF1 + Empa

Spleen (mg mm−1)

17.45 ± 0.38

16.55 ± 0.62

20.90 ± 0.32*

18.53 ± 0.81#

Liver (mg mm−1)

286.40 ± 12.58

264.80 ± 7.80

771.40 ± 34.64*

547.90 ± 21.37*,#

Kidney (mg mm−1)

40.52 ± 1.33

41.58 ± 1.34

55.22 ± 1.46*

54.92 ± 1.60*

Perirenal fat (mg mm−1)

11.32 ± 1.85

8.47 ± 1.63

183.70 ± 36.89*

100.60 ± 27.25*,#

Left lung (mg mm−1)

11.06 ± 0.20

10.65 ± 0.65

12.92 ± 0.69*

11.02 ± 0.25#

Dry weight of left lung (mg mm−1)

2.30 ± 0.03

2.16 ± 0.06

2.70 ± 0.08*

2.42 ± 0.06#

3 lobes of lung (mg mm−1)

17.94 ± 0.41

16.40 ± 0.41

21.48 ± 1.64*

17.23 ± 0.37#

Heart (mg mm−1)

31.93 ± 0.66

28.74 ± 0.75*

38.98 ± 0.95*

35.40 ± 0.63*,#

Tibial length (mm)

41.76 ± 0.35

42.54 ± 0.53

40.22 ± 0.42

39.89 ± 0.43

Weight (g)

407.70 ± 9.07

366.00 ± 7.67*

523.80 ± 19.93*

478.90 ± 8.73*,#

  1. Organs were weighted and indexed to the respective tibial length. Values are shown as mean ± SEM of n = 7–10 per group
  2. Empa empagliflozin
  3. * P < 0.05 vs control group and #P < 0.05 vs ZSF1 group